These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10728017)

  • 1. Assessing the optimal level of platelet inhibition with GPIIb/IIIa inhibitors in patients undergoing coronary intervention. Rationale and design of the GOLD study.
    Steinhubl SR
    J Thromb Thrombolysis; 2000 Apr; 9(3):199-205. PubMed ID: 10728017
    [No Abstract]   [Full Text] [Related]  

  • 2. Initial platelet activity may predict efficacy after chronic oral glycoprotein IIb/IIIa blockade: should we still consider uniform treatment regimens?
    Gurbel PA; McKenzie ME; Serebruany VL
    Thromb Res; 2000 Jul; 99(1):105-7. PubMed ID: 11012374
    [No Abstract]   [Full Text] [Related]  

  • 3. Monitoring platelet GP IIb/IIIa antagonist therapy.
    Coller BS
    Circulation; 1998 Jan 6-13; 97(1):5-9. PubMed ID: 9443422
    [No Abstract]   [Full Text] [Related]  

  • 4. The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists.
    White MM; Krishnan R; Kueter TJ; Jacoski MV; Jennings LK
    J Thromb Thrombolysis; 2004 Dec; 18(3):163-9. PubMed ID: 15815877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors.
    Lakkis NM; George S; Thomas E; Ali M; Guyer K; Carville D
    Catheter Cardiovasc Interv; 2001 Jul; 53(3):346-51. PubMed ID: 11458412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet glycoprotein IIb/IIIa inhibitors.
    Hellstrom HR
    Circulation; 2003 Feb; 107(5):E39-9. PubMed ID: 12578891
    [No Abstract]   [Full Text] [Related]  

  • 7. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
    Granada JF; Kleiman NS
    Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A propensity analysis of the impact of platelet glycoprotein IIb/IIIa inhibitor therapy on in-hospital outcomes after percutaneous coronary intervention.
    Sharma SK
    Am J Cardiol; 2004 Feb; 93(4):524-5. PubMed ID: 14969645
    [No Abstract]   [Full Text] [Related]  

  • 9. Optimizing antiplatelet therapy in coronary interventions.
    King SB
    Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-8-13. PubMed ID: 11129685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of anti-platelet monitoring in catheterization laboratory.
    Mukherjee D; Moliterno DJ
    J Thromb Thrombolysis; 2000 Apr; 9(3):293-301. PubMed ID: 10728030
    [No Abstract]   [Full Text] [Related]  

  • 11. Improving microvascular perfusion with platelet glycoprotein IIb/IIIa receptor inhibition.
    Dippel EJ
    J Invasive Cardiol; 2002 Dec; 14 Suppl E():12E-16E; quiz 17E. PubMed ID: 12668858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPIIb-IIIa receptor inhibitors: what the interventional radiologist needs to know.
    Hofmann LV; Razavi M; Arepally A; Reginelli JP; Resar J; Geschwind JF; Corl F
    Cardiovasc Intervent Radiol; 2001; 24(6):361-7. PubMed ID: 11907740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local delivery of glycoprotein IIb/IIIa receptor inhibitors using drug eluting stents.
    Gershlick AH
    Semin Interv Cardiol; 1998; 3(3-4):185-90. PubMed ID: 10406691
    [No Abstract]   [Full Text] [Related]  

  • 14. Glycoprotein IIb/IIIa inhibitor therapy and outcomes after percutaneous coronary intervention.
    Tepper RI; Simonian N
    Am J Cardiol; 2003 Sep; 92(6):771-2. PubMed ID: 12972136
    [No Abstract]   [Full Text] [Related]  

  • 15. Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
    Ronner E; Boersma E; Akkerhuis KM; Harrington RA; Lincoff AM; Deckers JW; Karsch K; Kleiman NS; Vahanian A; Topol EJ; Califf RM; Simoons ML
    Eur Heart J; 2002 Feb; 23(3):239-46. PubMed ID: 11792139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of platelets glycoprotein IIb/IIIa (GP IIb/IIIa) receptor: rationale for their use in clinical cardiology.
    Rossi ML; Zavalloni D
    Mini Rev Med Chem; 2004 Sep; 4(7):703-9. PubMed ID: 15379638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Glycoprotein (GP) IIb/IIIa platelet inhibitors in acute ischemic syndrome and percutaneous coronary intervention].
    Caramori PR; Casco JR; Zago AJ; Adelman AG
    Arq Bras Cardiol; 1998 Nov; 71(5):725-34. PubMed ID: 10347959
    [No Abstract]   [Full Text] [Related]  

  • 18. Antiplatelet use in interventional cardiology.
    Brodison A; Katira R; More RS; Chauhan A
    Postgrad Med J; 2000 Feb; 76(892):70-9. PubMed ID: 10644382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of activation-dependent platelet membrane glycoproteins in development of subacute occlusive coronary stent thrombosis.
    Gawaz M; Neumann FJ; Ott I; May A; Rüdiger S; Schömig A
    Coron Artery Dis; 1997; 8(3-4):121-8. PubMed ID: 9237020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring platelet GP IIb/IIIa [corrected] antagonist therapy.
    Coller BS
    Circulation; 1997 Dec; 96(11):3828-32. PubMed ID: 9403602
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.